Interchangeable Insulin Biosimilars: A Game Changer in Diabetes Management

home / pharmacist-view / interchangeable-insulin-biosimilars-a-game-changer-in-diabetes-management

The panel of experts in the management of diabetes review the role of insulin therapy and the place for biosimilars. They will review the approval process for biosimilars including the approval of the first interchangeable insulin biosimilar.

Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

EP. 1: Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Thomas C. Blevins, MD, ECNU, FACE, FNLA
December 1st 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

Challenges to Biosimilar Adoption of Insulin Glargine-yfgn

EP. 2: Challenges to Biosimilar Adoption of Insulin Glargine-yfgn

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Thomas C. Blevins, MD, ECNU, FACE, FNLA
December 1st 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Future Directions for the Use of Biosimilars in Diabetes

EP. 3: Future Directions for the Use of Biosimilars in Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Thomas C. Blevins, MD, ECNU, FACE, FNLA
December 1st 2021

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.

Addition of Pharmacists to Diabetes Management Teams Enhances Care

EP. 4: Addition of Pharmacists to Diabetes Management Teams Enhances Care

Marissa Fox
December 9th 2021

The addition of a pharmacist to a diabetes management team increases therapy optimization and medication access while enhancing patient care.

Role of Interchangeable Biosimilars in the Management of Diabetes

EP. 5: Role of Interchangeable Biosimilars in the Management of Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Thomas C. Blevins, MD, ECNU, FACE, FNLA
February 2nd 2022

Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.

Results of INSTRIDE Studies for Diabetes Management

EP. 6: Results of INSTRIDE Studies for Diabetes Management

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Thomas C. Blevins, MD, ECNU, FACE, FNLA
February 2nd 2022

Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.

Basal Insulin Therapies for Diabetes Management

EP. 7: Basal Insulin Therapies for Diabetes Management

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Thomas C. Blevins, MD, ECNU, FACE, FNLA
February 2nd 2022

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.

© 2025 MJH Life Sciences

All rights reserved.